Advertisement
Advertisement
U.S. Markets open in 7 hrs 59 mins
Advertisement
Advertisement
Advertisement
Advertisement

Phio Pharmaceuticals Corp. (PHIOW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.0232+0.0062 (+36.47%)
At close: 03:56PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0170
Open0.1309
Bid0.1033 x 2900
Ask0.1190 x 800
Day's Range0.0102 - 0.0273
52 Week Range0.0102 - 0.0273
Volume214,336
Avg. VolumeN/A
Market Cap421,414
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-1.1290
Earnings DateNov 10, 2020 - Nov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • InvestorPlace

    3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gains Today

    We’re seeing major movement from some hot penny stocks today and are diving into what has them on the rise! Source: John Brueske/Shutterstock.com Before we get too far in. Just remember that penny stocks are incredibly volatile. While that doesn’t mean these stocks are moving without reason, investors will want to do their due diligence before diving into any of these companies. With that warning out of the way, let’s get into the hot penny stocks news for Tuesday!InvestorPlace - Stock Market Ne

  • PR Newswire

    Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

    Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has received regulatory clearance to start a clinical trial with its lead product candidate, PH-762. The Company was granted the clinical trial authorization (CTA) by the French National Agency for the Safety of Medicines and Health Products (ANSM - L'Agence national

  • PR Newswire

    Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference

    Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn, will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is being held on January 10 – 13, 2022.

Advertisement
Advertisement